Clinical Trial Update: Bortezomib in Treating Patients With Lymphoproliferative Disorders [Phase 2]

View source ↗

Summary

Phase 2 study of bortezomib in recurrent lymphoproliferative disorders, including follicular lymphoma and mantle cell lymphoma; results were posted in 2014 afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-04-01